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March 2, 2010:926–33eneficial in terms of CV outcomes, but this was presumably
onfounded by the disadvantages of the atenolol-based regimen.
However, we did not focus on the variable predictability of HR
ecause that was not the purpose of the study. We wanted to know
hether having a higher baseline HR attenuated the superior
ffects on major CV events of the amlodipine-based compared
ith atenolol-based regimen. We could find no evidence of any
uch attenuation, and hence we believe that an increased baseline
R should not be an indication for preferential use of beta-
lockade in hypertensive populations without coronary heart dis-
ase. Even if baseline HR had not predicted CV outcomes in the
SCOT study, we believe that the same conclusion should be
rawn.
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leeding Risk on
arfarin Among Elderly
atients With Atrial Fibrillation
oli et al. (1) observed different rates of major hemorrhage between
atients younger than 80 years of age and 80 years of age and older.
s discussed by the authors, these rates differed considerably from
he rates of major hemorrhage observed among similarly aged
ohorts by Hylek et al. (2). We want to highlight an important
ethodological issue in the authors’ calculation of event rates. The puthors state, “the overall exposure to warfarin for each patient was
alculated in relation to aging, before and after his/her 80th
irthday.” Thus, the authors allowed crossover of prevalent war-
arin survivors from the younger cohort to the age 80 years
nception cohort. At the time of enrollment, the baseline age 80
ears cohort numbered 180 patients. Yet, in Table 1 of their article
1), the authors provide baseline characteristics for 327 patients in
he age 80 years group. The 2 age inception cohorts are distinct
nd should contribute person-years exclusively to their baseline
ssignment. Given this methodological error, the rates of hemor-
hage provided for the 2 inception cohorts are flawed. The reader
s also unable to compare baseline characteristics between the
ounger and age 80 years inception cohorts because the authors
ermitted crossover of 157 patients. In addition, the observation
eriod in the study by Hylek et al. (2) was intentionally truncated
t 1 year to provide the first-year experience on warfarin. Calcu-
ation of adverse event rates over years tends to enrich the
erson-year denominator with “survivors” because bleeding rates
re highest in the first 90 days of warfarin therapy. To accurately
eport rates of major hemorrhage among elderly individuals newly
tarting warfarin, the authors need to recalculate the bleeding rates
ccording to baseline group assignment without crossover between
he groups. To enable comparison of the 2 studies, events and
erson-years of observation would need to be restricted to the
atients’ first year of therapy. The anticipated results would be
igher bleeding rates and deterioration of time “in-range” as
eported.
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eply
e studied a cohort of atrial fibrillation patients on oral antico-
gulant treatment for stroke prophylaxis (1). Our patients were
outinely followed by the Anticoagulation Clinic of our institution
ith a median follow-up of 2.7 years, and some of them for as long
s 13 years. At the beginning of warfarin treatment, the mean age
f our cohort was 75 years; therefore, many patients reached the
ge of 80 years during follow-up. As stated in the article, we
ecided to analyze the occurrence of adverse events in relation to
ging to evaluate whether aging itself could be correlated with an
ncrease in bleeding risk that exceeds the advantages of stroke
revention. In reporting clinical characteristics of patients, we
